Advertisement

Science China Life Sciences

, Volume 61, Issue 8, pp 893–901 | Cite as

Role of EGFL7/EGFR-signaling pathway in migration and invasion of growth hormone-producing pituitary adenomas

  • Qian Liu
  • Junwen Zhang
  • Hua Gao
  • Taoyang Yuan
  • Jie Kang
  • Lu Jin
  • Songbai Gui
  • Yazhuo Zhang
Research Paper

Abstract

Currently, the primary therapeutic strategy for most growth hormone-producing pituitary adenomas (GHPA) is surgery. Due to the invasiveness of GHPA, high recurrence has limited the benefit of complete adenoma removal surgery. Epidermal growth factor-like domain 7 (EGFL7) is a secreted factor implicated in tumor angiogenesis, growth, invasiveness and metastasis in GHPA. Herein, we observed that the expression level of EGFL7 and p-EGFR in invasive GHPA was much higher than that of non-invasive GHPA. The overexpression of EGFL7 was positively correlated with activation of EGFR (p-EGFR). Noticeably, EGFL7 knockdown significantly inhibited activation of EGFR signaling cascades, including p-ERGR, p-AKT and p-ERK. Further studies showed that EGFL7 knockdown or pharmacological inhibition of EGFR-pathway, using EGFR inhibitor Tyrphostin AG-1478, significantly suppressed migration and invasion of GH3 and GT1-1 cells. In summary, our findings suggest that EGFL7 is a key factor for regulation of EGFR signaling pathway and plays an important role in migration and invasion of invasive GHPA.

Keywords

EGFL7 EGFR growth hormone-producing pituitary adenomas (GHPA) invasion tumorigenesis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

This work was supported by the National Natural Science Foundation of China (81502154), Research Special Fund For Public Welfare Industry of Health of China (201402008) and National High Technology Research and Development Program of China (2015AA020504).

Supplementary material

11427_2018_9320_MOESM1_ESM.ppt (4 mb)
Supplementary material, approximately 3.97 MB.

References

  1. Alexandru, O., Purcaru, S.O., Tataranu, L.G., Lucan, L., Castro, J., Folcuţi, C., Artene, S.A., Tuţă, C., and Dricu, A. (2018). The influence of EGFR inactivation on the radiation response in high grade glioma. Int J Mol Sci 19, 229.CrossRefPubMedCentralGoogle Scholar
  2. Avraham, R., and Yarden, Y. (2011). Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol 12, 104–117.CrossRefPubMedGoogle Scholar
  3. Bush, N.A.O., and Butowski, N. (2017). The effect of molecular diagnostics on the treatment of glioma. Curr Oncol Rep 19, 26.CrossRefPubMedGoogle Scholar
  4. Campagnolo, L., Leahy, A., Chitnis, S., Koschnick, S., Fitch, M.J., Fallon, J.T., Loskutoff, D., Taubman, M.B., and Stuhlmann, H. (2005). EGFL7 is a chemoattractant for endothelial cells and is up-regulated in angiogenesis and arterial injury. Am J Pathol 167, 275–284.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Chiasson-MacKenzie, C., and McClatchey, A.I. (2018). EGFR-induced cytoskeletal changes drive complex cell behaviors: the tip of the iceberg. Sci Signal 11, eaas9473.CrossRefPubMedGoogle Scholar
  6. Dhandapani, S., Singh, H., Negm, H.M., Cohen, S., Anand, V.K., and Schwartz, T.H. (2016). Cavernous sinus invasion in pituitary adenomas: systematic review and pooled data meta-analysis of radiologic criteria and comparison of endoscopic and microscopic surgery. World Neurosurgery 96, 36–46.CrossRefPubMedGoogle Scholar
  7. Díaz, R., Silva, J., García, J.M., Lorenzo, Y., García, V., Peña, C., Rodríguez, R., Muñoz, C., García, F., Bonilla, F., et al. (2008). Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosom Cancer 47, 794–802.CrossRefPubMedGoogle Scholar
  8. Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., and Han, W. (2016). Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 59, 468–479.CrossRefPubMedGoogle Scholar
  9. Geethadevi, A., Parashar, D., Bishop, E., Pradeep, S., and Chaluvally-Raghavan, P. (2017). ERBB signaling in CTCs of ovarian cancer and glioblastoma. Genes Cancer 8, 746–751.PubMedPubMedCentralGoogle Scholar
  10. Huang, C., Li, X., Zhou, Y., Luo, Y., Li, C., and Yuan, X. (2010). Expression and clinical significance of EGFL7 in malignant glioma. J Cancer Res Clin Oncol 136, 1737–1743.CrossRefPubMedGoogle Scholar
  11. Huang, C., Yuan, X., Li, Z., Tian, Z., Zhan, X., Zhang, J., and Li, X. (2014). VE-statin/Egfl7 siRNA inhibits angiogenesis in malignant glioma in vitro. Int J Clin Exp Pathol 7, 1077–1084.PubMedPubMedCentralGoogle Scholar
  12. Kwatra, M.M. (2017). A rational approach to target the epidermal growth factor receptor in glioblastoma. Curr Cancer Drug Targets 17, 290–296.CrossRefPubMedGoogle Scholar
  13. Liu, Q., Wang, J., Yang, H., Gao, H., Li, C., Lan, X., and Zhang, Y. (2018). Attenuation of EGFL7 expression inhibits growth hormone–producing pituitary adenomas growth and invasion. Hum Gene Ther doi: 10.1089/hum.2017.200.Google Scholar
  14. Lopes, M.B.S. (2017). The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134, 521–535.CrossRefPubMedGoogle Scholar
  15. Luo, W., Shao, C., Li, N., Zhang, F., Guo, S., Duan, Z., Zheng, Q., and He, H. (2015). Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma. Am J Transl Res 7, 1236–1245.PubMedPubMedCentralGoogle Scholar
  16. Mete, O., and Lopes, M.B. (2017). Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28, 228–243.CrossRefPubMedGoogle Scholar
  17. Nagata, Y., Inoshita, N., Fukuhara, N., Yamaguchi-Okada, M., Nishioka, H., Iwata, T., Yoshimoto, K., and Yamada, S. (2018). Growth hormoneproducing pituitary adenomas in childhood and young adulthood: clinical features and outcomes. Pituitary 21, 1–9.CrossRefPubMedGoogle Scholar
  18. Normanno, N., Bianco, C., Strizzi, L., Mancino, M., Maiello, M., Luca, A., Caponigro, F., and Salomon, D. (2005). The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6, 243–257.CrossRefPubMedGoogle Scholar
  19. Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M.R., Carotenuto, A., De Feo, G., Caponigro, F., and Salomon, D.S. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2–16.CrossRefPubMedGoogle Scholar
  20. Ntali, G., and Wass, J.A. (2018). Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas. Pituitary 21, 111–118.CrossRefPubMedGoogle Scholar
  21. Parker, L.H., Schmidt, M., Jin, S.W., Gray, A.M., Beis, D., Pham, T., Frantz, G., Palmieri, S., Hillan, K., Stainier, D.Y.R., et al. (2004). The endothelial-cell-derived secreted factor Egfl7 regulates vascular tube formation. Nature 428, 754–758.CrossRefPubMedGoogle Scholar
  22. Philippin-Lauridant, G., Baranzelli, M.C., Samson, C., Fournier, C., Pinte, S., Mattot, V., Bonneterre, J., and Soncin, F. (2013). Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer. Int J Oncol 42, 1367–1375.CrossRefPubMedGoogle Scholar
  23. Shi, Q., and Chen, Y.G. (2017). Interplay between TGF-β signaling and receptor tyrosine kinases in tumor development. Sci China Life Sci 60, 1133–1141.CrossRefPubMedGoogle Scholar
  24. Soncin, F., Mattot, V., Lionneton, F., Spruyt, N., Lepretre, F., Begue, A., and Stehelin, D. (2003). VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J 22, 5700–5711.CrossRefPubMedPubMedCentralGoogle Scholar
  25. Sun, L., Yu, S., Xu, H., Zheng, Y., Lin, J., Wu, M., Wang, J., Wang, A., Lan, Q., Furnari, F., et al. (2018). FHL2 interacts with EGFR to promote glioblastoma growth. Oncogene 37, 1386–1398.CrossRefPubMedGoogle Scholar
  26. Tampourlou, M., Fountas, A., Ntali, G., and Karavitaki, N. (2018). Mortality in patients with non-functioning pituitary adenoma. Pituitary 21, 203–207.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Wang, F.Y.F., Kang, C.S., Wang-Gou, S.Y., Huang, C.H., Feng, C.Y., and Li, X.J. (2017a). EGFL7 is an intercellular EGFR signal messenger that plays an oncogenic role in glioma. Cancer Lett 384, 9–18.CrossRefPubMedGoogle Scholar
  28. Wang, J., Liu, Q., Gao, H., Wan, D., Li, C., Li, Z., and Zhang, Y. (2017b). EGFL7 participates in regulating biological behavior of growth hormone-secreting pituitary adenomas via Notch2/DLL3 signaling pathway. Tumour Biol 39, 1–11.Google Scholar
  29. Wang, J., Zhang, Z., Li, R., Sun, W., Chen, J., Zhang, H., Shu, K., and Lei, T. (2017c). Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway. Life Sci 194, 150–156.CrossRefPubMedGoogle Scholar
  30. Wang, Y., Sun, H., Xiao, Z., Zhang, D., Bao, X., and Wei, N. (2017d). XWL-1-48 exerts antitumor activity via targeting topoisomerase II and enhancing degradation of Mdm2 in human hepatocellular carcinoma. Sci Rep 7, 9989.CrossRefPubMedPubMedCentralGoogle Scholar
  31. Worthylake, R., Opresko, L.K., and Wiley, H.S. (1999). ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274, 8865–8874.CrossRefPubMedGoogle Scholar
  32. Wu, F., Yang, L.Y., Li, Y.F., Ou, D.P., Chen, D.P., and Fan, C. (2009). Novel role for epidermal growth factor-like domain 7 in metastasis of human hepatocellular carcinoma. Hepatology 50, 1839–1850.CrossRefPubMedGoogle Scholar
  33. Zhu, W., and Qin, L. (2017). GOLM1-regulated EGFR/RTK recycling is a novel target for combating HCC metastasis. Sci China Life Sci 60, 98–101.CrossRefPubMedGoogle Scholar
  34. Zoli, M., Milanese, L., Bonfatti, R., Sturiale, C., Pasquini, E., Frank, G., and Mazzatenta, D. (2016). Cavernous sinus invasion by pituitary adenomas: role of endoscopic endonasal surgery. J Neurosurg Sci 60, 485–494.PubMedGoogle Scholar

Copyright information

© Science China Press and Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Qian Liu
    • 1
    • 3
  • Junwen Zhang
    • 1
  • Hua Gao
    • 1
    • 3
  • Taoyang Yuan
    • 2
  • Jie Kang
    • 2
  • Lu Jin
    • 2
  • Songbai Gui
    • 2
  • Yazhuo Zhang
    • 1
    • 2
    • 3
  1. 1.Beijing Neurosurgical InstituteCapital Medical UniversityBeijingChina
  2. 2.Beijing Tiantan HospitalCapital Medical UniversityBeijingChina
  3. 3.Key Laboratory of Central Nervous System Injury Research, Beijing Institute for Brain Disorders Brain Tumor Center, China National Clinical Research Center for Neurological DiseasesCapital Medical UniversityBeijingChina

Personalised recommendations